These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

198 related articles for article (PubMed ID: 15900799)

  • 1. The impact of biologics on the quality of life of psoriasis patients and the economics of psoriasis care.
    Stein KR; Pearce DJ; Feldman SR
    Semin Cutan Med Surg; 2005 Mar; 24(1):52-7. PubMed ID: 15900799
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Cost-effectiveness of systemic treatments for moderate-to-severe psoriasis in the German health care setting.
    Küster D; Nast A; Gerdes S; Weberschock T; Wozel G; Gutknecht M; Schmitt J
    Arch Dermatol Res; 2016 May; 308(4):249-61. PubMed ID: 26961372
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The economic impact of high-need psoriasis in daily clinical practice before and after the introduction of biologics.
    Driessen RJ; Bisschops LA; Adang EM; Evers AW; Van De Kerkhof PC; De Jong EM
    Br J Dermatol; 2010 Jun; 162(6):1324-9. PubMed ID: 20163420
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Real-world US healthcare costs of psoriasis for biologic-naive patients initiating apremilast or biologics.
    Feldman SR; Pelletier CL; Wilson KL; Mehta RK; Brouillette MA; Smith D; Bonafede MM
    J Comp Eff Res; 2019 Jan; 8(1):45-54. PubMed ID: 30387367
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The impact of biologic therapy in chronic plaque psoriasis from a societal perspective: an analysis based on Italian actual clinical practice.
    Polistena B; Calzavara-Pinton P; Altomare G; Berardesca E; Girolomoni G; Martini P; Peserico A; Puglisi Guerra A; Spandonaro F; Vena Gino A; Chimenti S; Ayala F
    J Eur Acad Dermatol Venereol; 2015 Dec; 29(12):2411-6. PubMed ID: 26370321
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cost-effectiveness of moderate-to-severe psoriasis treatment.
    Miller DW; Feldman SR
    Expert Opin Pharmacother; 2006 Feb; 7(2):157-67. PubMed ID: 16433581
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A new era in the management of psoriasis? The biologics: facts and controversies.
    Ferrándiz C; Carrascosa JM; Boada A
    Clin Dermatol; 2010; 28(1):81-7. PubMed ID: 20082956
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Biologic treatment sequences for plaque psoriasis: a cost-utility analysis based on 10 years of Dutch real-world evidence from BioCAPTURE.
    Klijn SL; van den Reek JMPA; van de Wetering G; van der Kolk A; de Jong EMGJ; Kievit W
    Br J Dermatol; 2018 May; 178(5):1181-1189. PubMed ID: 29247500
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combining biologic therapies with other systemic treatments in psoriasis: evidence-based, best-practice recommendations from the Medical Board of the National Psoriasis Foundation.
    Armstrong AW; Bagel J; Van Voorhees AS; Robertson AD; Yamauchi PS
    JAMA Dermatol; 2015 Apr; 151(4):432-8. PubMed ID: 25517130
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
    Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
    J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Medication adherence and health care costs associated with biologics in Medicaid-enrolled patients with psoriasis.
    Bhosle MJ; Feldman SR; Camacho FT; Timothy Whitmire J; Nahata MC; Balkrishnan R
    J Dermatolog Treat; 2006; 17(5):294-301. PubMed ID: 17092860
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Phototherapy, psoriasis, and the age of biologics.
    Richard EG; Hönigsmann H
    Photodermatol Photoimmunol Photomed; 2014 Feb; 30(1):3-7. PubMed ID: 24313462
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Costs of Common Psoriasis Medications, 2010-2014.
    James SM; Hill DE; Feldman SR
    J Drugs Dermatol; 2016 Mar; 15(3):305-8. PubMed ID: 26954315
    [TBL] [Abstract][Full Text] [Related]  

  • 14. A retrospective cohort study of the impact of biologic therapy initiation on medical resource use and costs in patients with moderate to severe psoriasis.
    Fonia A; Jackson K; Lereun C; Grant DM; Barker JN; Smith CH
    Br J Dermatol; 2010 Oct; 163(4):807-16. PubMed ID: 20662837
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Comparison of Management Guidelines for Moderate-to-Severe Plaque Psoriasis: A Review of Phototherapy, Systemic Therapies, and Biologic Agents.
    Ighani A; Partridge ACR; Shear NH; Lynde C; Gulliver WP; Sibbald C; Fleming P
    J Cutan Med Surg; 2019; 23(2):204-221. PubMed ID: 30463416
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Estimated cost efficacy of systemic treatments that are approved by the US Food and Drug Administration for the treatment of moderate to severe psoriasis.
    D'Souza LS; Payette MJ
    J Am Acad Dermatol; 2015 Apr; 72(4):589-98. PubMed ID: 25631851
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Costs of therapy with biologics in the treatment of moderate to severe plaque psoriasis in the context of the Italian health-care system.
    Terranova L; Mattozzi C; Richetta AG; Mantuano M; Cardosi L; Teruzzi C
    G Ital Dermatol Venereol; 2014 Feb; 149(1):131-43. PubMed ID: 24566574
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Paradoxical effects of cost reduction measures in managed care systems for treatment of severe psoriasis.
    Yentzer BA; Yelverton CB; Simpson GL; Simpson JF; Hwang W; Balkrishnan R; Feldman SR
    Dermatol Online J; 2009 Apr; 15(4):1. PubMed ID: 19450394
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Comparison of the cost-effectiveness of biologic drugs used for moderate-to-severe psoriasis treatment in the United States.
    Wu JJ; Feldman SR; Rastogi S; Menges B; Lingohr-Smith M; Lin J
    J Dermatolog Treat; 2018 Dec; 29(8):769-774. PubMed ID: 29658383
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Real-world treatment patterns and healthcare costs among biologic-naive patients initiating apremilast or biologics for the treatment of psoriasis.
    Wu JJ; Pelletier C; Ung B; Tian M
    J Med Econ; 2019 Apr; 22(4):365-371. PubMed ID: 30652520
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.